Stock Movers Keurig Dr Pepper Soars; Carter's Falls; Avidity Biosciences Rallies
Oct 27, 2025
Lisa Mateo, a Bloomberg reporter specializing in market news, dives into the latest corporate shifts. Keurig Dr Pepper is optimistic, raising its sales growth outlook while securing $7 billion for its JDE Peet’s acquisition. Meanwhile, Carter's faces challenges with a sales miss and plans to close stores and cut jobs. On a high note, Avidity Biosciences surges as Novartis agrees to acquire it for $12 billion, marking a major venture into new treatments. Tune in for these market movers and more!
AI Snips
Chapters
Transcript
Episode notes
Keurig Ups Outlook And Eases Deal Fears
- Keurig Dr Pepper raised its fiscal 2025 net sales outlook to high-single-digits after Q3 sales beat estimates.
- The company is separating its beverage and coffee businesses and raised $7 billion from Apollo and KKR to help fund the JDE Peet's acquisition.
Carter's Announces Store Closures And Cuts
- Carter's reported Q3 sales that missed estimates and suspended full-year guidance amid tariff headwinds.
- The company will close about 150 North American stores and cut office roles by roughly 15%, targeting $35 million in annual savings.
Novartis Makes Major Buy Of Avidity
- Novartis agreed to buy Avidity Biosciences in a deal valued at $12 billion, sending RNA shares sharply higher.
- The acquisition adds potential blockbuster neuromuscular treatments and allows Avidity to spin out early cardiology programs.